Tags

Type your tag names separated by a space and hit enter

Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.
Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):43-50.CE

Abstract

Combined estrogen and progestin hormone therapy (CHT) increases breast cancer risk, but this risk varies by breast cancer type. Several studies indicate that CHT is more strongly related to lobular carcinoma risk than to ductal carcinoma risk, but these studies have been limited in their assessments of recency and duration of use, and none included a centralized pathology review. We conducted a population-based case-control study consisting of 324 lobular, 196 ductal-lobular, and 524 ductal cases diagnosed from 2000 to 2004 and 469 controls ages 55 to 74 years old. Tissue specimens were centrally reviewed for 83% of cases. Associations between hormone use and breast cancer risk were evaluated using polytomous logistic regression. Current CHT users had 2.7-fold [95% confidence interval (95% CI), 1.7-4.2] and 3.3-fold (95% CI, 2.0-5.7) elevated risks of lobular and ductal-lobular carcinomas, respectively, regardless of tumor stage, size, or nodal status. Elevations in risk were observed only among users of CHT for > or =3 years. Among ductal-lobular cases, CHT increased risk of tumors that were > or =50% lobular (odds ratio, 4.8; 95% CI, 2.1-11.1) but not tumors that were <50% lobular (odds ratio, 1.9; 95% CI, 0.9-4.1). Current CHT users for > or =3 years have a substantially increased risk of lobular carcinomas. Although lobular carcinomas are less common than ductal carcinomas (approximately 16% versus 70% of all invasive breast cancers in the United States), this duration is shorter than the 5 years of use widely cited to be needed to confer an increased risk of breast cancer overall. Further studies focusing on the etiology of lobular carcinomas are needed.

Authors+Show Affiliations

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA. cili@fhcrc.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

18199710

Citation

Li, Christopher I., et al. "Relationship Between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-lobular Breast Carcinomas." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 17, no. 1, 2008, pp. 43-50.
Li CI, Malone KE, Porter PL, et al. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev. 2008;17(1):43-50.
Li, C. I., Malone, K. E., Porter, P. L., Lawton, T. J., Voigt, L. F., Cushing-Haugen, K. L., Lin, M. G., Yuan, X., & Daling, J. R. (2008). Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 17(1), 43-50. https://doi.org/10.1158/1055-9965.EPI-07-0558
Li CI, et al. Relationship Between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-lobular Breast Carcinomas. Cancer Epidemiol Biomarkers Prev. 2008;17(1):43-50. PubMed PMID: 18199710.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. AU - Li,Christopher I, AU - Malone,Kathleen E, AU - Porter,Peggy L, AU - Lawton,Thomas J, AU - Voigt,Lynda F, AU - Cushing-Haugen,Kara L, AU - Lin,Ming Gang, AU - Yuan,Xiaopu, AU - Daling,Janet R, PY - 2008/1/18/pubmed PY - 2008/4/2/medline PY - 2008/1/18/entrez SP - 43 EP - 50 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 17 IS - 1 N2 - Combined estrogen and progestin hormone therapy (CHT) increases breast cancer risk, but this risk varies by breast cancer type. Several studies indicate that CHT is more strongly related to lobular carcinoma risk than to ductal carcinoma risk, but these studies have been limited in their assessments of recency and duration of use, and none included a centralized pathology review. We conducted a population-based case-control study consisting of 324 lobular, 196 ductal-lobular, and 524 ductal cases diagnosed from 2000 to 2004 and 469 controls ages 55 to 74 years old. Tissue specimens were centrally reviewed for 83% of cases. Associations between hormone use and breast cancer risk were evaluated using polytomous logistic regression. Current CHT users had 2.7-fold [95% confidence interval (95% CI), 1.7-4.2] and 3.3-fold (95% CI, 2.0-5.7) elevated risks of lobular and ductal-lobular carcinomas, respectively, regardless of tumor stage, size, or nodal status. Elevations in risk were observed only among users of CHT for > or =3 years. Among ductal-lobular cases, CHT increased risk of tumors that were > or =50% lobular (odds ratio, 4.8; 95% CI, 2.1-11.1) but not tumors that were <50% lobular (odds ratio, 1.9; 95% CI, 0.9-4.1). Current CHT users for > or =3 years have a substantially increased risk of lobular carcinomas. Although lobular carcinomas are less common than ductal carcinomas (approximately 16% versus 70% of all invasive breast cancers in the United States), this duration is shorter than the 5 years of use widely cited to be needed to confer an increased risk of breast cancer overall. Further studies focusing on the etiology of lobular carcinomas are needed. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/18199710/Relationship_between_menopausal_hormone_therapy_and_risk_of_ductal_lobular_and_ductal_lobular_breast_carcinomas_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=18199710 DB - PRIME DP - Unbound Medicine ER -